RGL1 Inhibitors
RGL1 inhibitors function by disrupting the RAS pathway, which RGL1 is directly involved in. The RAS pathway is a critical cellular signaling pathway that regulates various cellular processes, including cell proliferation, differentiation, and survival. Some of the RGL1 inhibitors function by inhibiting Src family kinases (Saracatinib, Dasatinib), which can disrupt the activation of RAS and hence decrease the activation of RGL1. Other inhibitors work by inhibiting MEK1/2 (Selumetinib, Trametinib), BRAF (Vemurafenib, Dabrafenib), or RAF kinases (Sorafenib, Regorafenib). These molecules are part of the RAS pathway, and their inhibition can prevent the activation of RGL1.
Another group of RGL1 inhibitors function by inhibiting various kinases that can activate the RAS pathway. These inhibitors include multi-kinase inhibitors that inhibit VEGFR, PDGFR, and KIT (Lenvatinib, Sunitinib, Pazopanib), and a dual tyrosine kinase inhibitor that inhibits EGFR and HER2/neu (Lapatinib). By inhibiting these kinases, these inhibitors can decrease the activation of RGL1. The RGL1 inhibitors operate by disrupting the downstream signaling of the RAS pathway or by blocking the activation of the RAS pathway itself, both of which result in the decreased activation of RGL1.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
Saracatinib is a Src family kinase inhibitor. RGL1, a Ral guanine nucleotide dissociation stimulator, is involved in the RAS pathway. By inhibiting Src kinases, saracatinib can disrupt the activation of RAS, which would then decrease the activity of RGL1. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor. Since RGL1 is involved in the RAS pathway, inhibiting MEK1/2 can disrupt the downstream signaling of the RAS pathway, leading to decreased activation of RGL1. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is another MEK1/2 inhibitor. Similar to Selumetinib, Trametinib can decrease the activation of RGL1 by disrupting the downstream signaling of the RAS pathway. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib is a BRAF inhibitor. As BRAF is a part of the RAS pathway, inhibiting BRAF can prevent the activation of RGL1. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that can inhibit RAF kinases. Since RAF kinases are part of the RAS pathway, Sorafenib can decrease the activation of RGL1 by inhibiting RAF kinases. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib is another BRAF inhibitor. By inhibiting BRAF, Dabrafenib can prevent the activation of RGL1, as BRAF is a part of the RAS pathway. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that can inhibit RAF kinases, similar to Sorafenib. By inhibiting RAF kinases, Regorafenib can decrease the activation of RGL1 as RAF kinases are a part of the RAS pathway. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR, FGFR, PDGFR, RET, and KIT. These kinases can activate the RAS pathway. By inhibiting these kinases, Lenvatinib can decrease the activation of RGL1. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-kinase inhibitor that inhibits VEGFR, PDGFR, and KIT. Since these kinases can activate the RAS pathway, Sunitinib can decrease the activation of RGL1 by inhibiting these kinases. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is a multi-kinase inhibitor that inhibits VEGFR, PDGFR, and KIT, similar to Sunitinib. By inhibiting these kinases, Pazopanib can decrease the activation of RGL1. | ||||||